Compare stocks

MGRX vs OBIO

Mangoceuticals, Inc. Common Stock and Orchestra BioMed Holdings, Inc. Ordinary Shares

Compare the businesses

Mangoceuticals, Inc. Common Stock

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Open MGRX dashboard ↗

Orchestra BioMed Holdings, Inc. Ordinary Shares

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Open OBIO dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗